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SuMMAry – entecavir is a guanosine analogue with activity against hepatitis B virus. The 
aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naïve HBeAg-positive 
chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from 
the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4±41.5 
iu/l, and at the end of the 4-year study period, 90% of patients had alanine aminotransferase  values 
within the normal range. At week 96, 91.7% of patients had HBv DnA <300 copies; at month 48, 
90% of patients had HBv DnA <50 iu/ml. HBeAg loss was recorded in 7.1% of patients at week 
96 and in 12.5% at month 48. The rate of HBeAg seroconversion was 4.8% at week 96 and 7.5% at 
month 48. The rate of HBsAg seroconversion was 2.1% at week 96 and 2.5% at month 48. entecavir 
as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated 
therapy.
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Introduction
Chronic hepatitis B (CHB) infection is a major 
health problem caused by hepatitis B virus (HBv). 
CHB infection can lead to liver failure, liver cirrhosis 
(lC) and hepatocellular carcinoma (HCC), and af-
fects over 350 million people worldwide. HBv has 
a covalent closed circular DnA (cccDnA), which is 
the cause of the sustainability of the HBv. elimina-
tion of HBv is very difficult and the main purpose 
of therapy is to sustain viral suppression. Antiviral 
drugs that are used in the treatment of CHB include 
interferon [interferon-alpha (iFn-α) and pegylated 
(PeG) iFn-α] and nucleosides or nucleoside ana-
logues [entecavir (eTv), adefovir dipivoxil (ADv), 
telbivudine (ldT, β-l-2’-deoxythymidine), and lami-
vudine (lAM)]. nucleos(t)ide analogues (nA) target 
the reverse transcriptase of HBv. This group of drugs 
are potent inhibitors of viral replication. Studies have 
shown that continued therapy with nA can suppress 
viral replication over prolonged periods, and can re-
sult in delay or even prevention of clinical progres-
sion to liver cirrhosis and hepatocellular carcinoma. 
However, antiviral drug resistance limits the efficacy 
of these drugs1. Among nucleoside analogues, eTv 
is a strong new-generation nucleoside analogue. Ac-
cording to literature data, eTv proved advantageous 
for a higher rate of HBv DnA suppression and low 
drug-resistance2. However, in the literature, there is a 
limited number of studies evaluating the efficacy and 
safety of entecavir treatment in HBeAg positive naïve 
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CHB over a long period. For this reason, we aimed 
to assess the long-term, 4-year efficacy and safety of 
entecavir treatment in nucleos(t)ide-naïve HBeAg-
positive CHB patients with various baseline data.
Material and Methods
This multicenter study was conducted in the south-
east part of Anatolia, Turkey (Diyarbakir, Batman, 
Kiziltepe and Midyat). The study included 49 naïve 
HBeAg-positive CHB patients who had never taken 
nucleos(t)ide treatment, aged 22-60 years, treated with 
entecavir (0.5 mg/day) for 96 weeks and followed be-
tween 2007 and 2011 at the infectious Disease De-
partment, Dicle university Hosital, Diyarbakır Private 
German Hospital, Batman State Hospital and Midyat 
State Hospital. Serum HBv DnA level, alanine ami-
notransferase (AlT) activity, HBeAg, anti-HBe-an-
tibodies, HBsAg, anti-HBs, HBv DnA level, crea-
tinine level, and urea level were evaluated at baseline, 
and at weeks 12, 24, 48 and 96 during therapy. At the 
end of week 96, nine patients did not present for follow 
up examination and were excluded. The remaining 40 
patients continued presenting for follow up and contin-
ued to receive 0.5 mg/day entecavir therapy throughout 
the 4-year period. in the remaining 40 patients, serum 
AlT activity, HBeAg, anti-HBe-antibodies, HBsAg, 
anti-HBs, HBv DnA level, creatinine level and urea 
level were investigated and evaluated at month 36 (3 
years) and month 48 (4 years). 
in this study, the diagnosis of naïve HBeAg posi-
tive CHB was based on HBsAg positivity, HBeAg 
positivity, HBv DnA >105 copies/ml, ultrasonogra-
phy findings, and liver biopsy, as follows: 1) seroposi-
tive for HBsAg, serum AlT elevation for at least 6 
months (normal range: 13-31 u/l for females and 13-
53 u/l for males), and detectable serum HBv DnA; 
2) no evidence for hepatocellular carcinoma, hepatitis 
C virus, human immunodeficiency virus or hepatitis 
D virus infection; and 3) creatinine clearance of more 
than 70 ml per minute. liver biopsy was performed 
within 6 months of entry. liver histology was ana-
lyzed according to the criteria of ishak (comprising 
two major components: necroinflammation and fibro-
sis). Patients were excluded from the study if they had 
previously received nucleos(t)ide analogue or interfer-
on-alfa therapy3.
Hepatitis B surface antigen (HBsAg), HBeAg 
and hepatitis B e antibody (anti-HBe) (Abbott labo-
ratories, north Chicago, il, uSA) were assayed with 
the fourth generation enzyme linked immunosor-
bent assay. All patients underwent blood testing for 
liver biochemistry (AlT, AST, AlP, GGT, albumin, 
and bilirubin), complete blood count, prothrombin 
time, and renal biochemistry before commencement 
of therapy. Serum HBv-DnA was measured by the 
TaqMan polymerase chain reaction assay (TaqMan 
HBv Assay, roche Diagnostics; lower limit of quan-
tification = 35 copies/ml).
Statistical analyses were performed with the Sta-
tistical Package for Social Sciences version 15.0 soft-
ware (Friedman and Cochran Q tests). values of p less 
than 0.05 were considered significant.
Results
Results in 49 patients treated with entecavir (0.5 mg/
day) for 96 weeks
The patient mean age was 38.8±10.2 years. The 
initial mean value of AlT was 79.4±41.5 iu/l. At 
baseline, the mean fibrosis score (ishak) of liver biopsy 
was 2.27±0.75. Overall, 49 HBeAg positive patients 
completed treatment week 96. At treatment weeks 12, 
48 and 96, HBv DnA <300 copies were recorded in 
8.2%, 89.8% and 91.7% of patients, respectively. At 
treatment week 96, HBeAg loss was observed in 7.1%, 
HBeAg seroconversion in 4.8% and HBsAg serocon-
version in 2.1% of patients. At week 96, the mean AlT 
level was 32.6 iu/l, showing significant decrease as 
compared with the initial AlT level (Table 1). Treat-
ment safety was good. none of the patients had a con-
firmed creatinine increase of 0.5 mg/dl. renal safety 
was good. Creatinine remained stable throughout the 
96-week trial. 
Results in 40 patients having continued follow up and 
treatment with entecavir (0.5 mg/day) for 4 years
Among the patients that continued presenting 
for follow up, 92.5% achieved HBv DnA <50 iu/
ml at month 36 and 90% at month 48 of treatment. 
HBeAg loss was observed in 10% of patients at month 
36 and 12.5% at month 48. HBeAg seroconversion 
was observed in 5% of patients at month 36 and 7.5% 
at month 48. HBsAg loss was observed in 2.5% of 
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patients at month 36 and 5% at month 48. HBsAg se-
roconversion was recorded in 2.5% patients at month 
36 and 2.5% at month 48. in 92.5% of the 40 patients, 
AlT values  were within the normal range at the end 
of the third year and in 90% at the end of the fourth 
year. At the end of the fourth year, treatment safety 
was good. none of the patients had a confirmed cre-
atinine increase of 0.5 mg/dl, and renal safety was 
good.
Discussion
nucleos(t)ide analogues (nA) are potent inhibitors 
of viral replication. Continued therapy with nA can 
suppress viral replication over prolonged periods. Sup-
pression of viral replication causes delay or prevention 
of clinical progression to liver cirrhosis and hepatocel-
lular carcinoma. However, antiviral drug resistance is 
a major problem in antiviral-therapy of HBv infec-
tion due to the limited efficacy of these drugs1.
According to european guidelines, partial viro-
logic response (Pvr) is defined as a >1 log iu/ml 
decline in HBv DnA from baseline but a detectable 
load at week 24 or week 484.
entecavir is a strong new generation nucleoside 
analogue4. in the literature, there are a limited num-
ber of studies evaluating the efficacy and safety of 
eTv treatment in HBeAg positive naïve CHB pa-
tients for a long period. For this reason, we believe that 
our study, which investigated the 4-year (48 months) 
long-term efficacy and safety of entecavir treatment in 
nucleos(t)ide-naïve HBeAg-positive CHB patients, 
will contribute to clarifying the issue and can serve 
as a guide for the long-term treatment approach to 
nucleos(t)ide-naïve HBeAg-positive CHB patients.
To our knowledge, HBv DnA level is a primary 
prognostic marker for the treatment of patients with 
CHB. The early and sustained suppression of HBv 
DnA replication leads to improved long-term rates 
of virologic, serologic and biochemical responses. 
rapidly and effectively suppressing HBv DnA rep-
lication can decrease the incidence of lC, HCC and 
drug resistance2. in our study, 8.2% of nucleos(t)ide-
naïve HBeAg-positive CHB patients achieved HBv 
DnA <300 copies at week 12 of treatment, 89.8% at 
week 48, and 91.7% at week 96. Our study showed 
that with eTv, the great majority of nucleos(t)ide-
naïve HBeAg-positive CHB patients achieved HBv 
DnA <300 copies at week 48. in addition, we ob-
served that 92.5% of patients having continued pre-
senting for follow up achieved HBv DnA <50 iu/
ml at month 36 and 90% at month 48 of treatment. 
Based on our results, we suggest that eTv is an effi-
cacious agent suppressing HBv DnA replication for a 
long period. On the other hand, studies demonstrated 
that clearance of HBsAg was related to very low or 
undetectable HBv DnA [<300 copies/ml], normal-
ization of serum AlT levels, improvement in liver 
histology, a decreased risk of HCC, and prolonged 
survival5,6. in some long-term natural history studies, 
it was estimated that the rate of spontaneous HBsAg 
seroclearance was 0.5%-1.7% per year7-10. According 
to the literature, HBsAg seroclearance was observed 
less frequently in Asian patients (<1%/year), who typi-
cally acquire HBv at birth, than in western patients 
who mainly gain HBv later in life5,11. in a retrospec-
tive study of nucleoside-naïve hepatitis B e antigen 
(HBeAg)-positive CHB patients who achieved hepa-
titis B surface antigen (HBsAg) loss during eTv or 
lAM therapy for maximum duration of 96 weeks on-
treatment and 24 weeks off-treatment, HBsAg loss 
was confirmed in 5.1% of patients treated with eTv 
and 2.8% of patients treated with lAM. Among pa-
tients with HBsAg loss, 96% achieved HBv DnA 
<300 copies/ml, and 96% achieved HBeAg loss. This 
retrospective study revealed that HBsAg loss was re-
lated to sustained off-treatment suppression of HBv 
DnA12. in addition, HBeAg is a protein expressed by 
pre-C gene and HBeAg is lost with the rise of immu-
nomodulatory effect, which can suppress HBv DnA 
replication. HBeAg seroconversion is considered to be 
a marker of treatment response and to be related with 
improved clinical outcomes. it is one of the important 
withdrawal signs for HBeAg-positive patients and it 
is suggested that patients with HBeAg seroconver-
sion can achieve sustained immune response2. in our 
study, HBsAg seroconversion was observed in 2.1% of 
patients on treatment at week 96 and in 5% on treat-
ment at month 48. Furthermore, we observed HBeAg 
loss in 7.1% of patients on treatment at week 96 and in 
12.5% on treatment at month 48. in our country, gen-
otype D is the predominant genotype among patients 
with hepatitis B and it is known that CHB patients 
with genotype D have poor response to treatment. 
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We presumed that low HBsAg seroconversion rates 
and HBeAg loss rates in our study were related to the 
predominant genotype in Turkey.
in the literature, there are reports on some studies 
evaluating the efficacy and safety of eTv treatment in 
HBeAg positive nA-experienced patients with CHB; 
however, there are a limited number of studies inves-
tigating eTv as long-term monotherapy in nA-naïve 
patients. 
reijnders et al. investigated 161 CHB patients (34% 
nA-experienced) treated with eTv monotherapy. 
They found that 79% of nA-naïve patients achieved 
virologic response during a median follow up of 11 
months and 54% of nA-experienced patients during 
a median follow up of 12 months. They showed eTv 
to be an efficacious drug in nA-naïve patients. They 
also demonstrated that the antiviral efficacy of eTv 
was not influenced by prior treatment with ADv but 
that eTv should not be used in patients with previ-
ous lAM-resistance1. Sherman et al. also showed that 
antiviral efficacy of eTv was significantly decreased 
in patients with lAM-resistant mutations at the start 
of eTv monotherapy13. 
Jiyang et al. analyzed eTv-treated and ADv-
treated CHB patients. They found that the negative 
rate of HBeAg seroconversion was significantly in-
creased at 24 weeks in eTv-treated patients, whereas 
in ADv-treated patients, these changes were not sig-
nificant. According to their study, eTv showed sig-
nificantly decreased levels of HBv DnA at 24 weeks 
when compared with ADv; there was no difference in 
virologic response between the two treatments at any 
other time point. The AlT and total bilirubin lev-
els were significantly decreased at 12 weeks in both 
eTv-treated and ADv-treated patients without dif-
ferences between the two treatments14.
leung et al. found that the mean decrease in serum 
HBv DnA and the proportion of patients achieving 
HBv DnA less than 300 copies/ml were greater in 
eTv-treated than ADv-treated patients at weeks 2, 
4, 8, 12, 24 and 48. At week 48, 3% of eTv-treated 
versus 47% of ADv-treated patients had HBv DnA 
of 105 copies/ml or more, and they suggest that eTv 
therapy resulted in earlier and superior reduction in 
HBv DnA compared with ADv in nucleoside-naïve 
HBeAg-positive CHB patients15. in their 96-week 
study, Gish et al. found that 74% of eTv-treated 
versus 37% of lAM-treated patients achieved HBv 
DnA <300 copies/ml, and 79% of eTv-treated 
versus 68% of lAM-treated patients had normalized 
AlT levels. Similar proportions of eTv-treated and 
lAM-treated patients achieved HBeAg seroconver-
sion (11% vs. 12%)16.
All of these comparative studies have shown that 
entecavir has superiority when compared to many 
known drugs used in the treatment of nA-naïve CHB 
patients. recent studies have shown that ldT is the 
strongest oral bioavailable nucleoside analogue. it can 
effectively suppress HBv DnA replication, and has 
a higher rate of hepatitis B e antigen (HBeAg) sero-
conversion than other current oral antiviral agents17. 
However, studies have shown that its drug-resistance 
Table 1. Results of entecavir treatment at week 96
Week 96 HBv DnA <300 copies/ml HBe Ag loss
n % p n % p
Age (yrs) <40 28 100.0 0.025 3 10.7 0.255
≥40 16 80.0 0 0.0
Gender Female 18 90.0 1.000 3 15.0 0.066
Male 26 92.9 0 0.0
Fibrosis <3 26 86.7 0.290 2 6.7 1.000
≥3 14 100.0 1 7.1
HAi <7 26 92.9 0.614 1 3.6 0.543
≥7 14 87.5 2 12.5
Baseline AlT <70 11 73.3 0.007 0 0.0 0.542
>70 33 100.0 3 9.1
Ai = histology activity index; AlT = alanine aminotransferase
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remains high. in a comparative study of eBv and 
ldT, Su et al. found that at 4 weeks and 8 weeks of 
treatment, the rates of HBeAg loss and HBeAg se-
roconversion were similar for eBv and ldT, while 
at weeks 12, 24, 48 and 52, the rate was higher in 
the ldT group than in the eTv group. However, at 
weeks 60 and 72, there was no significant difference 
in the rate of HBeAg seroconversion between the two 
groups in their study. in addition, between week 4 and 
week 72, there were no statistical differences in the 
rate of AlT normalization between the two groups3. 
According to literature data, it appears that drug re-
sistance of ldT limits its use in long-term therapy, but 
eTv can be used for a long period in patients with 
nA-naïve CHB3.
in a multicenter cohort study, it was observed 
that virologic response (HBv DnA <80 iu/ml) was 
achieved in 48%, 76% and 90% of HBeAg-positive, 
and in 89%, 98% and 99% of HBeAg-negative nA-
naïve patients at weeks 48, 96 and 144, respectively; 
21% of nA-naïve patients with at least 48-week fol-
low up had a detectable load at week 48 (partial viro-
logic response); 81% of patients with partial virologic 
response reached virologic response during prolonged 
eTv monotherapy, and none of them developed 
eTv-resistance. They found that eTv was safe and 
did not affect renal function or cause lactic acidosis; 
the authors suggest that eTv monotherapy can be 
continued in nA-naïve patients with detectable HBv 
DnA at week 48, particularly in those with a low 
viral load because long-term eTv leads to virologic 
response in the vast majority of patients3. Chang et 
al. also report that extended therapy with eTv for 5 
years maintained or increased the rates of HBv DnA 
suppression and AlT normalization. Additional pa-
tients also achieved HBeAg loss and seroconversion. 
entecavir provided sustained viral suppression with 
minimal resistance during long-term treatment of 
HBeAg positive CHB patients18.
in addition, we observed that the mean values of 
AlT as an indicator of therapeutic response declined 
during therapy and creatinine remained stable. Ac-
cording to our results on HBsAg loss, HBaAg sero-
conversion, HBeAg loss and HBeAg seroconversion, 
we can say that in short-term treatment of CHB, 
eTv was not superior, but based on our long-term 
results eTv could be used in long-term treatment of 
nucleoside-naïve CHB patients. entecavir had a high 
genetic barrier to resistance and proved to be a safe 
agent.
in conclusion, the results of this long-term study 
of eTv showed that among HBeAg-positive pa-
tients, therapy with eTv for 4 years achieved and 
maintained high rates of HBv DnA suppression and 
normal AlT levels. entecavir was also well tolerated 
throughout the 4-year administration. With its safety, 
viral suppression, and resistance profile, eTv is now 
considered a preferred choice for long-term treatment 
of nucleoside-naïve HBeAg-positive CHB patients.
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Sažetak
ČeTverOGODiŠnJA STuDiJA uČinKOviTOSTi i SiGurnOSTi enTeKAvirA u BOleSniKA S 
KrOniČniM HePATiTiSOM B POZiTivniH nA HBeAg BeZ PreTHODne nuKleOZ(T)iDne 
TerAPiJe
M. K. Celen, T. Dal, C. Ayaz, K. Bayan, D. Mert, O. Deveci i E. K. Oruc
entekavir je analog gvanozina koji djeluje protiv virusa hepatitisa B. Cilj ove četverogodišnje studije bio je procijeniti 
liječenje entekavirom kod bolesnika s kroničnim hepatitisom B pozitivnih na HBeAg bez prethodne nukleoz(t)idne te-
rapije. ukupno je 49 bolesnika primalo entekavir, a devetoro ih se povuklo s terapije na kraju 96. tjedna. Početna srednja 
vrijednost alanin aminotransferaze bila 79,4±41,5 iu/l, dok je nakon 4 godine vrijednost alanin aminotransferaze bila u 
normalnim granicama kod 90% bolesnika. u 96. tjednu je <300 kopija HBv DnA zabilježeno u 91,7% bolesnika, a u 48. 
mjesecu je 48,90% bolesnika imalo <50 iJ/ml HBv DnA. Gubitak HBeAg zabilježen je u 7,1% bolesnika u 96. tjednu te 
u 12,5% bolesnika u 48. mjesecu. Stopa serokonverzije HBeAg iznosila je 4,8% u 96. tjednu i 7,5% u 48. mjesecu. Stopa 
serokonverzije HBsAg bila je 2,1% u 96. tjednu i 2,5% u 48. mjesecu. Sigurnost terapije bila je dobra. Bolesnici su dobro 
podnosili entekavir, snažan i siguran lijek koji dovodi do ustaljenog suzbijanja virusa.  
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